This site uses cookies. By continuing to browse the site you are agreeing to our policy on the use of cookies. Find out more here.

eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
New eMC coming June 2013...

Genus Pharmaceuticals

Park View House, 65 London Road, Newbury, Berkshire, RG14 1JN
Telephone: +44 (0)1635 568 400
Fax: +44 (0)1635 568 401
Medical Information Direct Line: +44 (0)870 851 0207
Medical Information e-mail: genus@medinformation.co.uk
Customer Care direct line: +44 (0)1635 568 445
Medical Information Fax: +44 (0)1793 710 387

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 04/09/2009
SPC Anacal Rectal Ointment


Go to top of the page
1. Name of the medicinal product

Anacal Rectal Ointment


Go to top of the page
2. Qualitative and quantitative composition

Mucopolysaccharide polysulphuric acid ester (Heparinoid) 0.2%w/w

Oxypolyethoxydodecane (Lauromacrogol 400) 5.0%w/w


Go to top of the page
3. Pharmaceutical form

Rectal Ointment


Go to top of the page
4. Clinical particulars

Go to top of the page
4.1 Therapeutic indications

Anacal rectal ointment is indicated for the treatment of the following conditions:

Relief of symptoms associated with haemorrhoids (including perianal haematomas), perianal eczema, pruritus, anal fissure, proctitis, periproctitis, and aftercare of haemorrhoids treated by surgery or injection.


Go to top of the page
4.2 Posology and method of administration

Adults and the elderly:

To be applied one to four times daily.

Children:

Not recommended.


Go to top of the page
4.3 Contraindications

Known sensitivity to any active or inactive component of the formulation.

Not recommended for use in children.


Go to top of the page
4.4 Special warnings and precautions for use

If condition persists or worsens, seek medical advice.


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

There is no evidence to suggest that Anacal Rectal Ointment should not be used during pregnancy and lactation.


Go to top of the page
4.7 Effects on ability to drive and use machines

None.


Go to top of the page
4.8 Undesirable effects

None known.


Go to top of the page
4.9 Overdose

In the absence of any reports of the accidental ingestion of Anacal, no specific advice is available. General supportive measures may be appropriate.


Go to top of the page
5. Pharmacological properties

Go to top of the page
5.1 Pharmacodynamic properties

Mucopolysaccharide polysulphate ester is recognised as having:

A weak inhibitory effect on PGE2 synthesis and an indirect effect on LTB4 production based on in vitro studies.

Anti-coagulant activity: as a heparinoid.

Thrombolytic activity: through potentiation of urokinase activity.

Anti-exudatory activity: through inhibition of hyaluronidase.

Oxypolyethoxydodecane has both topical anaesthetic and anti-pruritic properties.


Go to top of the page
5.2 Pharmacokinetic properties

Radiochemical studies of absorption following cutaneous application of mucopolysaccharide polysulphate have shown that between 0.3 and 4% of the mucopolysaccharide administered is absorbed by various tissues (other than the treated area) within the first 8 hours. Typically between 1.7% and 4.6% will be absorbed within 2 to 4 days. Animal studies have also shown that mucopolysaccharide is bound intracellularly within the subcutis. Peak serum concentrations following cutaneous application are below the threshold of physiological relevance for coagulation.

Mucopolysaccharide is excreted in the urine partly unchanged and partly as depolymerized, shorter chain length molecules.


Go to top of the page
5.3 Preclinical safety data

None stated


Go to top of the page
6. Pharmaceutical particulars

Go to top of the page
6.1 List of excipients

Polyethylene highpolymer 1500 HSE

Liquid paraffin BP

Sorbitan stearate BP

Methylhydroxybenzoate BP


Go to top of the page
6.2 Incompatibilities

None.


Go to top of the page
6.3 Shelf life

3 years.


Go to top of the page
6.4 Special precautions for storage

Store below 25ºC.


Go to top of the page
6.5 Nature and contents of container

Lacquered aluminium tubes containing 30gm.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
7. Marketing authorisation holder

Genus Pharmaceuticals Limited,

Park View House

65 London Road,

Newbury,

Berkshire,

RG14 1JN


Go to top of the page
8. Marketing authorisation number(s)

PL 06831/0172


Go to top of the page
9. Date of first authorisation/renewal of the authorisation

02 February 2006/ 18 March 2009


Go to top of the page
10. Date of revision of the text

18 March 2009



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/4999/SPC/


Active Ingredients/Generics